FDA Approval of KOMZIFTI Marks Major Step for Hard-to-Treat AML

The FDA’s approval of KOMZIFTI™ (ziftomenib) represents a significant milestone for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring NPM1 mutations—one of the most common genetic drivers of the disease. NPM1 mutations occur in about 30% of AML cases, yet effective treatment options remain limited. Roughly 20% of patients do not respond to initial therapy, and of those who do, nearly 70% relapse within three years, driving an urgent need for therapies that offer deeper and more durable remissions.

The approval is based on data from the pivotal KOMET-001 trial, which evaluated 112 adults with R/R NPM1-mutated AML. KOMZIFTI achieved a 21.4% rate of complete remission (CR) or CR with partial hematologic recovery (CRh), with a median response duration of five months. Most responses—88%—occurred within the first six months of treatment, and the median time to initial response was 2.7 months. These results align with findings recently published in the Journal of Clinical Oncology.

Eunice Wang, M.D., of Roswell Park Comprehensive Cancer Center, highlighted KOMZIFTI’s favorable safety profile and lack of drug-drug interactions, noting its value for older patients or those unable to tolerate intensive chemotherapy. While the drug includes a boxed warning for differentiation syndrome, other common side effects were manageable and consistent with expectations for targeted AML therapies.

Kyowa Kirin’s Chief Medical Officer, Takeyoshi Yamashita, Ph.D., emphasized that the approval reinforces the growing role of precision medicines in hematologic cancers. KOMZIFTI is part of a global collaboration between Kura Oncology and Kyowa Kirin, with Kura leading U.S. development and manufacturing. To support access, Kura has launched the patient assistance program Kura RxKonnect™, designed to reduce barriers to treatment and reimbursement.